We recently published an article titled Jim Cramer’s Game Plan: 15 Stocks in Focus. In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against the other stocks featured in Jim Cramer’s Game Plan.
Jim Cramer, the host of Mad Money, discussed the upcoming market and corporate activity to look forward to this week, which will be dominated by earnings reports from various companies and an important inflation report from the Labor Department.
Cramer noted that Friday marked the heavy market focus on the prospect of the White House imposing tariffs on imports from Mexico, Canada, and China. As expected, the tariffs were announced, 25% from Mexico and Canada, and 10% from China, and the market, which had already been struggling, dropped further.
READ ALSO: Jim Cramer Looked Closely At These 10 Stocks and Jim Cramer’s Thoughts on These 7 Stocks
Cramer noted that the Dow plunged by 337 points, the S&P 500 fell 0.5%, and the Nasdaq declined by 0.28%. Adding fuel to the fire, President Trump later commented that he was “not concerned about the market’s reaction.” Cramer, reflecting on this, wished he could share that same sense of ease. He added:
“Finally, on Friday, we get the Labor Department’s non-farm payroll and right now the Fed is concerned that the economy might be running too hot. If we get robust job growth with higher wages, then I doubt we’ll see any rate hikes in the first half of the year.”
He then posed the question: if investors are hoping for a rising stock market, what would they want to see? Cramer explained that a job report that’s just “so-so” would be ideal, strong enough to keep rate cuts on the table, but not so strong as to hinder quarterly earnings.
“Bottom line: When you get a week that’s packed with important earnings reports and the monthly employment report plus the tariff news, you’re usually better off sitting on your hands because there’s just too much data for any individual to process even for an AI-powered individual. By the way, oh, let’s just throw in this DeepSeek stuff, which has made tech too maddening to buy or sell and too, let’s say boring. So if in doubt, do nothing.”
Our Methodology
For this article, we compiled a list of 15 stocks that were discussed by Jim Cramer during the episode of Mad Money on January 31. We listed the stocks in the order that Cramer mentioned them. We also provided hedge fund sentiment for each stock as of the third quarter of 2024, which was taken from Insider Monkey’s database of 900 hedge funds.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points (see more details here).
A medical technician wearing protective gloves and a mask mixing a biopharmaceutical solution.
Pfizer Inc. (NYSE:PFE)
Number of Hedge Fund Holders: 80
Cramer expects to hear good news from Pfizer Inc.’s (NYSE:PFE) fourth-quarter and full-year 2024 earnings report.
“We also hear from two huge drug companies, Merck and Pfizer… Pfizer bought Seagen, the old Seattle genetics at the end of 2023. We still haven’t seen the breakout anti-cancer drugs that would justify the deal’s $43 billion price tag. Now maybe we’ll hear something good this quarter. If so, the stock could soar, very little downside at these low levels… Then again, if you want yield in this market, I’d much rather own Merck or Pfizer.”
Pfizer (NYSE:PFE) develops and distributes biopharmaceuticals across various therapeutic areas, including cardiovascular health, infectious diseases, cancer, immunology, and vaccines. The company projects full-year 2025 revenues between $61.0 billion and $64.0 billion, with COVID-19 product revenues expected to remain consistent with 2024, excluding a non-recurring $1.2 billion from Paxlovid in 2024.
Pfizer (NYSE:PFE) expects operational revenue growth for 2025 to range from flat to 5% year-over-year, based on its 2024 baseline guidance. Additionally, the company expects adjusted diluted EPS for 2025 to be between $2.80 and $3.00, reflecting a year-over-year growth of 10% to 18% from the midpoint of its 2024 baseline guidance.
Overall PFE ranks 5th on our list of the stocks featured in Jim Cramer’s Game Plan. While we acknowledge the potential of PFE as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than PFE but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: 20 Best AI Stocks To Buy Now and Complete List of 59 AI Companies Under $2 Billion in Market Cap.
Disclosure: None. This article was originally published at Insider Monkey.
